Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-03-06
2007-03-06
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S397000, C514S400000, C546S274100, C548S340100, C548S311700
Reexamination Certificate
active
10405989
ABSTRACT:
The invention provides Aryl substituted imidazoles, pyrazoles, pyridizines and related compounds of the Formulawhere the variables are defined herein.Such compounds are ligands of C5a receptors. Preferred compounds of the invention act bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptos. This invention also relates to pharmaceutical compositions comprising such compounds. It further relates to the use of such compounds in treating a variety of inflammatory and immune system disorders.
REFERENCES:
patent: 5159083 (1992-10-01), Thurkauf et al.
patent: 5428164 (1995-06-01), Thurkauf et al.
patent: 5478934 (1995-12-01), Yuan et al.
patent: 5633376 (1997-05-01), Thurkauf et al.
patent: 5633377 (1997-05-01), Thurkauf et al.
patent: 5646280 (1997-07-01), Thurkauf et al.
patent: 5681956 (1997-10-01), Thurkauf et al.
patent: 6723743 (2004-04-01), Thurkauf et al.
patent: 6884815 (2005-04-01), Thurkauf et al.
patent: WO 02/14265 (2002-02-01), None
Cecil Textbook of Medicine, 20thedition (1996), vol. 2, pp. 2050-2057.
Cecil Textbook of Medicine, 20th edition (1996), vol. 2, pp. 1992-1996.
FDA mulls drug to slow late-stage Alzheimer's [online], [retrieved on Sep. 23, 2003]. Retrieved from the Internet,URL;http://www.cnn.com/2003/HEALTH/conditions/09/24/alzheimers.drug.ap/index.html>.
Database CA on STN, (Columbus, OH, USA), No. 128:3703, Thurkauf, et al. ‘Preparation of 4-aryl substituted piperazinylmethylphenyl imidazoles as a new class of dopamine receptor subtype specific ligands’, abstract, Oct. 28, 1997.
Database CA on STN, (Columbus, OH, USA), No. 123:55767, Thurkauf, et al. '2-Phenyl-4-(aminomethyl)imidazoles as potential antipsychotic agents. Synthesis and dopamine D2 receptor binding, abstract, J. Med. Chem., vol. 38, No. 12, pp. 2251-2255, 1995.
Database CA on STN, (Columbus, OH, USA), No. 117: 2513500350, Thurkauf, etal., ‘Preparation of (aminomethyl)phenylimidazoles as dopamine receptor ligands,’ abstract, Jul. 23, 1992.
Database CA on STN, (Columbus, OH, USA), No. 105:191381, Shiga, et al., ‘Silane derivatives,’ abstract, Mar. 24, 1986.
Database CA on STN, (Columbus, OH, USA), No. 131:257737, He, et al., ‘Enantioselective total synthesis of aspidophytine,’ abstract, J. Am. Chem. Soc., vol. 121, No. 28, pp. 6771-6772, 1999.
Drug Report for “C5a antagonists”, Merck & Co., from the Investigational Drugs database, search done Feb. 18, 2002, last update Apr. 17, 2001. Summary, 1 page.
de Laszio et al., “A Nonpeptide Agonist Ligand of the Human C5A Receptor: Synthesis, Binding Affinity Optimization and Functional Characterization,”Bioorganic&Medicinal Chemistry Lettersvol. 7, No. 2 pp. 213-218 and pp. 907-912 (1997).
Shilcrat, et al, “A New Regioselective Synthesis of 1,2,5-Trisubstituted 1H-Imidazoles and its Application to the Development of Eprosartan”, J. Org. Chem. 1997, 62, pp. 8449-8454.
U.S. Appl. No. 10/853,731, filed May 24, 2004, Thurkauf et al.
M. Abe, et al., “Contribution of Anaphylatoxin C5a to Late Airway Responses After Repeated Exposure of Antigen to Allergic Rats”,The American Association of Immunologists, vol. 167, pp. 4651-4660 (2001).
T. Woodruff, et al., “Antiarthritic Activity of an Orally active C5a Receptor Antagonist Against Antigen-Induced Monarticular Arthritis in the Rat”,Arthritis&Rheumatism, vol. 46, No. 9, pp. 2476-2485 (Sep. 2002).
F. Niculescu, et al., Complement activation and atherosclerosis,Molecular Immunology, vol. 36, pp. 949-955 (1999).
R. Riley, et al., “Recombinant Human Complement C5a Receptor Antagonist Reduces Infarct Size after Surgical Revascularization”,The Journal of Thoracic and Cardiovascular Surgery, vol. 120, No. 2, pp. 351-358 (2000).
H. Sumichika, “C5a receptor antagonists for the treatment of inflammation”,Current Opinion in Investigational Drugs, vol. 5, No. 5, pp. 505-510 (2004).
Promics, “Another positive performance for Promics' Anti-Anflammatory Drug PMX53,” www.promics.com.au
ews
ewitem.asp?itemid=50&archive=true (Mar. 10, 2004).
Chenard Bertrand L.
Gao Yang
Maynard George D.
Thurkauf Andrew
Zhao He
Alexander John B.
Anderson Rebecca
Corless Peter F.
Neurogen Corporation
Saeed Kamal A.
LandOfFree
Aryl imidazoles and related compounds as C5a receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aryl imidazoles and related compounds as C5a receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aryl imidazoles and related compounds as C5a receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3805374